The spread of COVID-19 continues due to genetic variation in SARS-CoV-2. Highly mutated
variants of SARS-CoV-2 have an increased transmissibility and immune evasion. Due to the …

Coronavirus disease 2019 (COVID-19) is an emerging global pandemic with severe
morbidity and mortality caused by the severe acute respiratory syndrome coronavirus 2 …

Drug repurposing approach was applied to find a potent antiviral agent against RNA viruses
such as SARS-CoV-2, influenza viruses and dengue virus with a concise strategy of small …

The spread of COVID-19 infection continues due to the emergence of multiple transmissible
and immune-evasive variants of the SARS-CoV-2 virus. Although various vaccines have …

Molnupiravir is a β-d-N4-hydroxycytidine-5′-isopropyl ester (NHC) compound that exerts
antiviral activity against various RNA viruses such as influenza, SARS, and Ebola viruses …

Abstract Molnupiravir, EIDD-2801/MK-4482, the prodrug of the ribonucleoside analog ß-d-
N4-hydroxycytidine (NHC), has activity against a number of RNA viruses including severe …

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) constitutes a major worldwide public health threat …

Among the seven coronaviruses that infect humans, HCoV-229E, HCoV-OC43, HCoV-NL63,
and HCoV-HKU1 usually cause mild and common cold symptoms; however, infection with …

Molnupiravir, a prodrug of the nucleoside derivative β-DN 4-hydroxycytidine (NHC), is
currently in clinical trials for COVID-19 therapy. However, the biochemical mechanisms …

Abstract β-DN 4-hydroxycytidine (NHC, EIDD-1931) is a nucleoside analogue that exhibits
broad spectrum antiviral activity against a variety of RNA viruses. Herein, we report the …